Literature DB >> 15261427

Malignant pleural mesothelioma in Turkey, 2000-2002.

Salih Emri1, Ahmet U Demir.   

Abstract

Both asbestos and erionite related malignant pleural mesothelioma (MPM) is a serious health problem in Turkey. Erionite has a higher potency in the lung than asbestos and familial clustering of malignant mesothelioma suggests a genetic predisposition to this cancer among affected individuals. Neither Simian virus 40 (SV40) nor human herpes virus 8 (HHV-8) are co-factors in the pathenogenesis of environmentally induced mesothelioma. A survival advantage has been demonstrated in patients with asbestos-induced mesothelioma compared with erionite-induced mesothelioma. This together with the proliferation index (PI) can be used as an independent prognostic factor for patients with malignant pleural mesothelioma. It is envisaged that the application of these prognostic approaches together with the new TNM staging system will allow investigations to be more precisely carried out and evaluated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261427     DOI: 10.1016/j.lungcan.2004.04.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  3 in total

1.  High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestos.

Authors:  Abdurrahman Abakay; Abdullah Cetin Tanrikulu; Mustafa Ayhan; Mehmet Sefik Imamoglu; Mahsuk Taylan; Muhammet Ali Kaplan; Ozlem Abakay
Journal:  Environ Health Prev Med       Date:  2015-12-21       Impact factor: 3.674

2.  Residential proximity to naturally occurring asbestos and mesothelioma risk in California.

Authors:  Xue-lei Pan; Howard W Day; Wei Wang; Laurel A Beckett; Marc B Schenker
Journal:  Am J Respir Crit Care Med       Date:  2005-06-23       Impact factor: 21.405

3.  Malignant pleural mesothelioma: a single-center experience in Turkey.

Authors:  Ahmet Sezer; Ahmet Taner Sümbül; Hüseyin Abalı; Hüseyin Mertsoylu; Ozgür Ozyılkan
Journal:  Med Sci Monit       Date:  2014-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.